HLA-E and HLA class I molecules on bone marrow and peripheral blood polymorphonuclear cells of myelodysplatic patients

Leukemia Research

Volumn 37, Issue 2, 2013, Pages 169-174

  Terrazzano, Giuseppe ^a,b   Alfinito, Fiorella ^b   Palatucci, Anna Teresa ^b   Rubino, Valentina ^b   Pepa, Roberta Della ^b   Giovazzino, Angela ^b   Ruggiero, Giuseppina ^b  

^a UNIVERSITY OF BASILICATA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CTL; HLA E; HLA I; Immune profile; MDS; NK

Indexed keywords

HLA ANTIGEN CLASS 1; HLA E ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CD8+ T LYMPHOCYTE; CELL SELECTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LOW RISK POPULATION; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REFRACTORY THROMBOCYTOPENIA; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; UPREGULATION;

BONE MARROW CELLS; CASE-CONTROL STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS;

EID: 84872409091     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.09.015     Document Type: Article

References (31)

1. Heaney M.L., Golde D.W. Myelodysplasia. N Engl J Med 1999, 340:1649-1660.
2. Baumann I., Scheid C., Koref M.S., Swindell R., Stern P., Testa N.G. Autologous lymphocytes inhibit haemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 2002, 30:1405-1411.
3. Epperson D.E., Nakamura R., Saunthararaja Y., Melenhorst J., Barrett A.J., Oligoclonal T cell expansion in Myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001, 25:1075-1083.
4. Maciejewski J.P. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem Cytochem 2007, 45:5-14.
5. Sloand E.M., Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008, 45:39-48.
6. Ruggiero G., Sica M., Luciano L., Savoia F., Cosentini E., Alfinito F., et al. A case of myelodysplastic syndrome associated with CD14(+)CD56(+) monocytosis, expansion of NK lymphocytes and defect of HLA-E expression. Leuk Res 2009, 33:181-185.
7. Luzzatto L., Bessler M., Rotoli B. Somatic mutations in Paroxysmal Nocturnal Hemoglobinuria: a blessing in disguise?. Cell 1997, 88:1-4.
8. Barrett J., Saunthararajah Y., Molldrem J. Myelodysplastic syndrome and aplastic anaemia: distinct entities or diseases linked by a common pathophysiology?. Semin Hematol 2000, 37:15-29.
9. Killick S.B., Mufti G., Cavenagh J.D., Mijovic A., Peacock J.L., Gordon-Smith E.C., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120:679-684.
10. Molldrem J.J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., et al. Antithymocyte Globulin for treatment of the bone marrow failure associated with Myelodysplastic Syndromes. Ann Intern Med 2002, 137:156-163.
11. Greenberg F., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
13. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:693-701.
14. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
15. Zeng W., Miyazato A., Chen G., Kajigaya S., Young N.S., Maciejewski J.P. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006, 107:167-175.
16. Nowbakht P., Ionescu M.C., Rohner A., Kalberer C.P., Rossy E., Mori L. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005, 105:3615-3622.
17. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
18. Terrazzano G., Sica M., Gianfrani C., Mazzarella G., Maurano F., De Giulio B., et al. Gliadin regulates the NK-dendritic cell cross-talk by HLA-E surface stabilization. J Immunol 2007, 179:372-381.
19. Marin R., Ruiz-Cabello F., Pedrinaci S., Méndez R., Jiménez P., Geraghty D.E., et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003, 54:767-775.
20. Majumder D., Bandyopadhyay D., Chandra S., Mukherjee N., Banerjee S. Lack of HLA-E surface expression is due to deficiency of HLA-E transcripts in the malignant hematopoietic cells of leukemic patients. Leuk Res 2006, 30:242-245.
21. Fischer L., Hummel M., Burmeister T., Schwartz S., Thiel E. Skewed expression of natural-killer (NK)-associated antigens on lymphoproliferations of large granular lymphocytes (LGL). Hematol Oncol 2006, 24:78-85.
22. Warren H.S., Christiansen F.T., Witt C.S. Functional inhibitory human leucocyte antigen class I receptors on natural killer (NK) cells in patients with chronic NK lymphocytosis. Br J Haematol 2003, 121:793-804.
23. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25+high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
24. + regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23:510-518.
25. Alfinito F., Sica M., Luciano L., Pepa R.D., Palladino C., Ferrara I., et al. Immune dysregulation and dyserythropoiesis in MDS. Br J Haematol 2010, 148:90-98.
26. Zinkernagel R.M., Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974, 48:701-702.
27. Germain R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76:287-299.
28. Ploegh H.L. Viral strategies of immune evasion. Science 1998, 280:249-253.
29. Seliger B., Ritz U., Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 2006, 118:129-138.
30. Barrett A.J. Myelodysplastic syndrome: an example of misguided immune surveillance?. Leuk Res 2004, 28:1123-1124.
31. Sloand E.M., Wu C.O., Greenberg P., Young N.S., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26:2505-2511.